TNF and inflammatory bowel disease: The introduction of biological treatments such as monoclonal anti-TNF-α antibodies, which have demonstrated clinical efficacy, represents a major recent advance in IBD therapy, but these treatments also increase the risk of infection and hypersensitivity [10,11].